Fagron N.V. Logo

Fagron N.V.

ISIN

BE0003874915

Ticker

FAGR

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Belgium

Year Founded

1990

About Fagron N.V.

Company Description

Fagron is active in 35 countries in EMEA, North America, and Latin America. Fagron has sterile and non-sterile compounding facilities in Europe (the Netherlands, Belgium, and the Czech Republic), Israel, the United States, Colombia, and South Africa, which supply medications to pharmacies, hospitals, and clinics, as well as directly to patients in South Africa and Colombia.

With over 400 pharmacists within Fagron, we are focused on providing a unique range of high-quality products based on scientific data and insights. The Fagron Brands are unique concepts developed by our R&D specialists to provide pharmacies and clients with exclusive pharmaceutical dosage forms and active pharmaceutical ingredients (APIs). We can provide solutions for all steps inside a compounding setting, either equipment, excipients, APIs, packaging, and much more.

Served Area

Worldwide

Headquarters

Venecoweg 20A
9810, Nazareth, Oost-Vlaanderen
Belgium

Insider Trades

Date Trading entity / Person Association Trade type Volume
25.03.2024 Padilla Rafael Board Buy EUR 18,820.34
19.12.2023 AOC Pharma S.à r.l. Close relation Buy EUR 16,500,000.00
05.12.2023 AOC Pharma S.à r.l. Close relation Buy EUR 3,001,250.00
20.10.2023 AOC Pharma S.à r.l. Close relation Buy EUR 7,748.65
19.10.2023 De Jong Cornelia Neeltje Board Buy EUR 38,750.00
04.08.2022 Padilla Rafael Board Buy EUR 49,945.00
03.12.2021 De Jong Cornelia Neeltje Board Buy EUR 27,280.00
02.12.2021 De Jong Cornelia Neeltje Board Buy EUR 33,250.00
01.12.2021 Van Rietschoten Constantijn Executive member Buy EUR 33,375.00
30.11.2021 Verlinden Johan Executive member Buy EUR 66,199.70

Capital Markets Information

ISIN

BE0003874915

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Brussels

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.